Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Warm Autoimmune Hemolytic Anemia Market to Observe Stunning Growth at a 14.4% CAGR During the Forecast Period (2026-2036) Due to the Emergence of Novel Drug Classes Such as FcRn Inhibitors, BTK Inhibitors, BAFF-R, and Others | DelveInsight

prnewswire.com
JNJ Johnson & Johnson's drug, IMAAVY (nipocalimab), targeting FcRn, is in Phase II/III trials for wAIHA. The article highlights its potential to transform the market by reducing pathogenic IgG antibodies, contributing to a positive outlook for the company in this therapeutic area. SNY Sanofi's drug, WAYRILZ (rilzabrutinib), a BTK inhibitor, is in Phase III for wAIHA. Its mechanism targets underlying disease drivers through immune modulation, positioning Sanofi to benefit from the evolving wAIHA market with a novel therapeutic approach. NVS Novartis' ianalumab, a BAFF-R targeting monoclonal antibody, is in Phase III for wAIHA with a regulatory submission anticipated by 2027. This development suggests a positive future for Novartis in the wAIHA market with a novel mechanism of action. INCY Incyte is mentioned as having a drug, Tafasitamab-cxix, under development for wAIHA. While listed among key companies, the article provides no specific details on its development stage or market impact, resulting in a neutral sentiment.

Warm Autoimmune Hemolytic Anemia Market to Observe Stunning Growth at a 14.4% CAGR During the Forecast Period (2026-2036) Due to the Emergence of Novel Drug Classes Such as FcRn Inhibitors, BTK Inhibitors, BAFF-R, and Others | DelveInsight The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive therapies such as corticosteroids, rituximab, and other nonspecific agents. Current pipeline developments are steering the market toward targeted, mechanism-based immune modulation, with advanced-stage therapies focusing on critical pathways underlying IgG-mediated hemolysis. Key candidates driving this shift include IMAAVY from Johnson & Johnson, WAYRILZ from Sanofi, and ianalumab from Novartis.

LAS VEGAS, June 30, 2026 /PRNewswire/ -- Recently published Warm Autoimmune Hemolytic Anemia Market Insights report includes a comprehensive understanding of current treatment practices, warm autoimmune hemolytic anemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Warm Autoimmune Hemolytic Anemia Market Summary

Discover competitors of Sanofi warm autoimmune hemolytic anemia marketed products @ https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market

Key Factors Driving the Growth of the Warm Autoimmune Hemolytic Anemia Market

Ramandeep Singh, Senior Consultant of Forecasting at DelveInsight, said that the active late-stage innovation, Phase III programs including IMAAVY, WAYRILZ, and Ianalumab, reflect a strong industry commitment. Singh further added that these agents target distinct immunologic checkpoints, providing mechanistic diversity and reducing reliance on generalized immunosuppression.

Warm Autoimmune Hemolytic Anemia Market Analysis

Warm Autoimmune Hemolytic Anemia Competitive Landscape

Some of the wAIHA drugs under development include IMAAVY (nipocalimab) (Johnson & Johnson), WAYRILZ (rilzabrutinib) (Sanofi), Ianalumab (Novartis), Tafasitamab-cxix (Incyte), and others.

Johnson & Johnson's Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor (FcRn), thereby preventing IgG recycling and lowering circulating levels of pathogenic IgG antibodies. By reducing the concentration of disease-causing autoantibodies, it may offer therapeutic benefit in IgG-driven disorders such as warm autoimmune hemolytic anemia (wAIHA), where autoantibodies contribute to the destruction of red blood cells. The therapy is currently being assessed in a Phase II/III clinical study for patients with wAIHA.

Sanofi's WAYRILZ is the first Bruton's Tyrosine Kinase (BTK) inhibitor being developed for immune thrombocytopenia (ITP), with a mechanism aimed at addressing the underlying drivers of disease through broad immune modulation. BTK is expressed in B cells, macrophages, and other innate immune cells, where it plays a central role in immune-mediated and inflammatory pathways. The drug is presently undergoing Phase III clinical evaluation for the treatment of wAIHA.

Novartis' Ianalumab is a monoclonal antibody that targets the B-cell activating factor receptor (BAFF-R). It is designed to inhibit BAFF-R signaling while simultaneously promoting B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC). Novartis expects to submit a regulatory application for ianalumab in wAIHA by 2027. The candidate is currently being investigated in a Phase III clinical trial for the treatment of wAIHA.

The anticipated launch of these emerging therapies are poised to transform the warm autoimmune hemolytic anemia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the warm autoimmune hemolytic anemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about warm autoimmune hemolytic anemia treatment options @ Warm Autoimmune Hemolytic Anemia Therapy

Recent Developments in the Warm Autoimmune Hemolytic Anemia Market

What is Warm Autoimmune Hemolytic Anemia?

Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disorder in which the body's immune system mistakenly produces autoantibodies that target and destroy its own red blood cells at normal body temperature. This premature destruction of red blood cells, known as hemolysis, leads to anemia and can result in symptoms such as fatigue, weakness, shortness of breath, dizziness, jaundice, and an increased heart rate. wAIHA may occur as a primary condition or develop secondary to other diseases, including autoimmune disorders, infections, or certain cancers. The condition is typically diagnosed through laboratory tests such as the direct antiglobulin test and blood counts. Treatment strategies aim to reduce immune-mediated red blood cell destruction and may include corticosteroids, immunosuppressive therapies, biologics, or, in some cases, splenectomy.

Warm Autoimmune Hemolytic Anemia Epidemiology Segmentation

The warm autoimmune hemolytic anemia epidemiology section provides insights into the historical and current warm autoimmune hemolytic anemia patient pool and forecasted trends for the leading markets. In the United States, primary wAIHA accounted for around 20,500 diagnosed prevalent cases in 2025, while secondary wAIHA comprised approximately 22,200 cases.

The warm autoimmune hemolytic anemia treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

Warm Autoimmune Hemolytic Anemia Market Report Metrics

Details

Study Period

2022–2036

Coverage

7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Warm Autoimmune Hemolytic Anemia Therapy Treatment Market CAGR

14.4 %

Warm Autoimmune Hemolytic Anemia Market Size in 2025

USD 600 Million

Key Warm Autoimmune Hemolytic Anemia Companies

Johnson & Johnson, Sanofi, Novartis, Incyte, and others

Key Warm Autoimmune Hemolytic Anemia Therapies

IMAAVY (nipocalimab), WAYRILZ (rilzabrutinib), Ianalumab, Tafasitamab-cxix, and others

Scope of the Warm Autoimmune Hemolytic Anemia Market Report

Download the report to understand which warm autoimmune hemolytic anemia therapies are in development @ Warm Autoimmune Hemolytic Anemia Clinical Trials

Table of Contents

1

Warm Autoimmune Hemolytic Anemia Market Key Insights

2

Warm Autoimmune Hemolytic Anemia Market Report Introduction

3

wAIHA Market Overview at a Glance

3.1

Market Share (%) Distribution of wAIHA by Therapies in the 7MM in 2025

3.2

Market Share (%) Distribution of wAIHA by Therapies in the 7MM in 2036

4

Executive Summary

5

Key Events

6

Disease Background and Overview

6.1

Introduction

6.2

Classification

6.3

Signs and Symptoms

6.4

Risk Factors

6.5

Pathophysiology

6.6

Diagnosis

6.7

Treatment

6.8

Diagnosis and Treatment Guidelines

7

Epidemiology and Market Forecast Methodology

8

Epidemiology and Patient Population

8.1

Key Findings

8.2

Assumptions and Rationale

8.2.1

Diagnosed Prevalent Cases of AIHA

8.2.2

Diagnosed Prevalent Cases of wAIHA

8.2.3

Type-specific Diagnosed Prevalent Cases of wAIHA

8.2.4

Gender-specific Diagnosed Prevalent Cases of wAIHA

8.2.5

Age-specific Diagnosed Prevalent Cases of wAIHA

8.2.6

Severity-specific Diagnosed Prevalent Cases of wAIHA

8.3

Diagnosed Prevalent Cases of AIHA in the 7MM

8.4

Diagnosed Prevalent Cases of wAIHA in the 7MM

8.5

The United States

8.5.1

Diagnosed Prevalent Cases of wAIHA in the United States

8.5.2

Type-specific Cases of wAIHA in the United States

8.5.3

Gender-specific Cases of wAIHA in the United States

8.5.4

Age-specific Cases of wAIHA in the United States

8.5.5

Severity-specific Cases of wAIHA in the United States

8.5.6

Treated Cases of wAIHA in the United States

8.6

EU4 and the UK

8.7

Japan

9

Patient Journey

10

Emerging wAIHA Drugs

10.1

Key Cross Competition

10.2

IMAAVY (nipocalimab): Johnson & Johnson

10.2.1

Product Description

10.2.2

Other Developmental Activities

10.2.3

Clinical Development

10.2.3.1

Clinical Trial Information

10.2.4

Safety and Efficacy

10.2.5

Analyst Views

10.3

WAYRILZ (rilzabrutinib): Sanofi

10.4

Ianalumab: Novartis

11

wAIHA Market– 7MM Market Analysis

11.1

Key Findings

11.2

Key Warm Autoimmune Hemolytic Anemia Market Forecast Assumptions

11.3

Warm Autoimmune Hemolytic Anemia Market Outlook

11.4

Conjoint Analysis

11.5

Market Size of wAIHA in the 7MM

11.6

Market Size of wAIHA by Therapies in the 7MM

11.7

The United States Warm Autoimmune Hemolytic Anemia Market Size

11.7.1

Total Market Size of wAIHA in the United States

11.7.2

Market Size of wAIHA by Therapies in the United States

11.8

EU4 and the UK Warm Autoimmune Hemolytic Anemia Market Size

11.9

Japan Warm Autoimmune Hemolytic Anemia Market Size

12

Key Opinion Leaders' Views

12.1

Expert/KOL Interview Highlights

13

Unmet Needs

14

SWOT Analysis

15

Warm Autoimmune Hemolytic Anemia Market Access and Reimbursement

15.1

The United States

15.2

In EU4 and the UK

15.3

Japan

16

Bibliography

17

Warm Autoimmune Hemolytic Anemia Market Report Methodology

Related Reports

Warm Autoimmune Hemolytic Anemia Clinical Trial Analysis

Warm Autoimmune Hemolytic Anemia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key wAIHA companies, including Johnson & Johnson, Sanofi, Novartis, Immunovant Sciences GmbH, Apellis Pharmaceuticals, Inc., Bioverativ, and others.

BTK Inhibitors Market

BTK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key BTK inhibitors companies, including BeiGene, Nurix Therapeutics, Roche, Genentech, Sanofi, Principia Pharma, Novartis, ACEA Therapeutics, InnoCare Pharma, and others.

FcRn Inhibitors Market

FcRn Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key FcRn inhibitors companies, including Immunovant, Viridian Therapeutics, argenx, UCB, Johnson & Johnson, and others.

Iron Deficiency Anemia Market

Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key iron deficiency anemia companies including Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysi, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

[email protected]

+14699457679

www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP